Company Monitoring Page for Biomarin

job ratings (see below graph) for Biomarin

job ratings for Biomarin

09/22/23
industry:
Biotechnology
company:
Biomarin
job rating:
1
Many executive VP who coast avoiding responsibility
09/13/23
industry:
Biopharma
company:
Biomarin
job rating:
1
Company is in a desperate shape
09/08/23
industry:
Biopharma
company:
Biomarin
job rating:
1
Top management incompetent. Some are just disgrace
09/06/23
industry:
Biotech
company:
Biomarin
job rating:
2
Bad company
08/10/23
industry:
pharma
company:
Biomarin
job rating:
2
Weak research
07/12/23
industry:
Pharmaceuticals
company:
Biomarin
job rating:
1
CEO compensation in 2022 18.4 mln Net profit zero Business model rare diseases Meaning nonprofit like with no profit showing, but the top raking a lot of money
06/28/23
industry:
pharma
company:
Biomarin
job rating:
1
Top heavy and poor management. People on H1b visas come in, but soon are gone. Cheap, unreliable labor and no contribution.
06/12/23
industry:
Biopharma
company:
Biomarin
job rating:
1
Agree on Biomarin. They want to be big pharma therefore hire some old big pharma misfits who try to implement the old stale concepts that do not work

Pages

latest headlines for company on cafepharma

Another phenylketonuria hold, courtesy of Homology
EP Vantage
Tue, 02/22/22 - 10:43 am
Tags:
Homology Medicines, HMI-102, Biomarin, BMN 307, FDA, clinical trials, clinical hold, PKU
BioMarin says gene therapy hold will endure as FDA questions cancer risk
BioPharma Dive
Sun, 02/20/22 - 11:54 am
Tags:
Biomarin, FDA, gene therapy, clinical trials
FDA grounds BioMarin gene therapy trial for months with demand for tumor risk data
Fierce Biotech
Fri, 02/18/22 - 10:32 am
Tags:
Biomarin, FDA, clinical trials, clinical hold, BMN 307, PKU, gene therapy
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts
Fierce Biotech
Mon, 01/10/22 - 11:32 am
Tags:
Biomarin, hemophilia A, gene therapy, valrox, clinical trials
FDA approves first drug for genetic cause of dwarfism
Stat
Fri, 11/19/21 - 11:06 am
Tags:
Biomarin, FDA, dwarfism, achondroplasia, Voxzogo
BioMarin's new launch Voxzogo could surprise investors and become a blockbuster brand: analyst
Fierce Pharma
Mon, 11/15/21 - 12:24 pm
Tags:
Biomarin, FDA, Voxzogo, dwarfism
Go or go go? J&J’s cell therapy heads to the FDA
EP Vantage
Fri, 10/29/21 - 10:33 am
Tags:
JNJ, cilta-cel, Multiple Myeloma, FDA, Biomarin, Merck, molnupiravir
Looking to win back investor confidence, BioMarin preps for its ‘largest launch’
Endpoints
Thu, 10/28/21 - 10:47 am
Tags:
Biomarin, Voxzogo, drug launches, achrondoplasia
5 FDA approval decisions to watch in the fourth quarter
BioPharma Dive
Sun, 10/3/21 - 08:32 pm
Tags:
FDA, vaccines, COVID-19, Pfizer, BioNTech, JNJ, cilta cel, Biomarin, vosoritide, Intra-Cellular Therapies, lumateperone, Moderna Therapeutics
FDA halts tests of BioMarin drug amid heightened focus on gene therapy safety
BioPharma Dive
Tue, 09/7/21 - 10:51 am
Tags:
FDA, Biomarin, gene therapy, phenylketonuria, clinical trials
BioMarin stands tall with first approved drug for rare disease that causes dwarfism
MedCity News
Sat, 08/28/21 - 08:57 pm
Tags:
Biomarin, Europe, achondroplasia, dwarfism, Incyte, MorphoSys
Get Ready for a Potential Double in This Biopharmaceutical Stock in the Next 6 to 12 Months
Motley Fool
Fri, 08/20/21 - 10:57 am
Tags:
Biomarin, Voxzogo
BioMarin gears up for two 'transformational' launches, Voxzogo and Roctavian: CEO
Fierce Pharma
Mon, 08/2/21 - 09:36 pm
Tags:
Biomarin, Pharma CEOs, J.J. Bienaimé
BioMarin's gene therapy lead jumps ship to rival biotech Vedere Bio II
Fierce Biotech
Tue, 06/22/21 - 11:11 am
Tags:
Vedere Bio II, gene therapy, Biomarin
BioMarin (BMRN) Hemophilia Gene Therapy Gets FDA's RMAT Tag
Yahoo/Zacks.com
Tue, 03/9/21 - 10:37 am
Tags:
Biomarin, gene therapy, hemophilia A, valoctocogene roxaparvovec, FDA, RMAT
Gene therapy for hemophilia: So close, yet so far away
BioPharma Dive
Thu, 01/28/21 - 11:18 pm
Tags:
hemophilia, hemophilia A, hemophilia B, gene therapy, Biomarin, uniQure
10 key clinical trials to watch in the first half of 2021
BioPharma Dive
Sun, 01/17/21 - 05:01 pm
Tags:
clinical trials, Novavax, AstraZeneca, JNJ, vaccines, COVID-19, Biomarin, Amgen, Merck, Pfizer, Roche, SAGE Therapeutics, Biogen, Vertex Pharmaceuticals
BioMarin tries to get hemophilia gene therapy back on track with positive data
BioPharma Dive
Mon, 01/11/21 - 10:40 am
Tags:
Biomarin, hemophilia A, gene therapy, clinical trials, Roctavian
10 Biopharma Stories to Look Forward to in 2021
BioSpace
Sun, 01/3/21 - 04:39 pm
Tags:
pandemic, COVID-19, vaccines, Joe Biden, drug pricing, M&A, venture capital, JNJ, Biomarin, Bluebird Bio, TG Therapeutics, Biogen, AstraZeneca
#ASH20 Best of the Rest: Pfizer, Sangamo launch a durability charge at BioMarin in hem A; The data behind Merck's $4.5B buyout
Endpoints
Mon, 12/7/20 - 10:32 am
Tags:
ASH2020, uniQure, hemophilia A, Sangamao, gene therapy, Biomarin

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.